Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.
Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L, Krosnjar N, Quigley K, Yaung K, Villa Bs M, Takahashi M, Jovanovic B, Oyama Y.
Burt RK, et al.
JAMA. 2006 Feb 1;295(5):527-35. doi: 10.1001/jama.295.5.527.
JAMA. 2006.
PMID: 16449618
Clinical Trial.
Secondary end points included SLE Disease Activity Index (SLEDAI), serology (antinuclear antibody [ANA] and anti-double-stranded (ds) DNA), complement C3 and C4, and changes in renal and pulmonary organ function assessed before treatment and at 6 months, 12 months, and the …
Secondary end points included SLE Disease Activity Index (SLEDAI), serology (antinuclear antibody [ANA] and anti-double-stranded (ds) …